Lumos Diagnostics, a Sarasota, Fla.-based healthcare company that provides complete point-of-care (POC) diagnostic test solutions that utilize proprietary digital reader platforms to allow healthcare professionals to diagnose and manage diseases and medical conditions, closed a U.S. $15m Series A funding.
Planet Innovation, an Australia-based healthtech innovation and commercialization company, made the investment.
The company intends to use the funds for the international commercial expansion of the FebriDx® rapid point-of-care (POC) test, the FebriDx U.S. FDA pivotal clinical trial, and additional development and manufacturing resources for its full-service POC business.
A spinout from Planet Innovation, Lumos Diagnostics merged with RPS Diagnostics in May 2019, creating a diverse healthcare company that combines the FebriDx test and commercial experience with a novel and proprietary digital reader platform.
Led by Robert Sambursky, MD, president and chief executive officer, Lumos Diagnostics provides assay development and manufacturing services for customized POC tests as well as directly develops, manufactures and will commercialize a suite of proprietary branded POC tests that focus on the systemic host immune response. FebriDx is a rapid POC test that provides clinicians with an in-office assessment of the body’s immune response to acute respiratory infection (ARI). The single-use FebriDx test identifies patients of all ages within 10 minutes who have a clinically significant underlying infection and aids in the differentiation of viral and bacterial ARIs through the simultaneous detection of both Myxovirus resistance protein A (MxA) and C-reactive protein (CRP) directly from a fingerstick blood sample.